Investors are rushing into the relative safe haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
President Donald Trump on Thursday directed the U.S. intelligence community to "quickly and fully cooperate" with Attorney General William Barr's investigation into the...Politicsread more
The U.S. Commerce Department said its proposed rule would amend the normal countervailing duty process to include new criteria for currency undervaluation.World Economyread more
Asia Pacific markets traded mixed on Friday morning as investors remained worried over trade tensions between the United States and China.Asia Marketsread more
Wall Street is becoming convinced that both the White House and Beijing are willing to engage in a protracted trade war that could begin to hit consumers and slow global...Market Insiderread more
Stocks fell sharply on Thursday as investors started to fear the U.S.-China trade war is slowing the economy.Marketsread more
"The last thing I want is to put a date out there for lifting the grounding," said Dan Elwell, acting administrator for the FAA.Transportationread more
The charges allege he published secret documents obtained by former Army intelligence analyst Chelsea Manning, some of which included the disclosure of foreigners who were...Politicsread more
TransferWise, the money transfer start-up, was valued at $3.5 billion after investors bought $292 million of shares in a secondary sale.Technologyread more
See which stocks are posting big moves after the bell on Thursday, May 23.Market Insiderread more
Sentiment is "not negative enough to trigger a huge rally ... unless we get some kind of real breakthrough with China," Jim Cramer says.Mad Money with Jim Cramerread more
(Adds details on Botox, Restasis sales, CEO and analyst comment, background)
May 7 (Reuters) - Allergan Plc raised its profit and revenue forecasts for the year on Tuesday as it beat expectations for quarterly profit, fueled by higher sales of its blockbuster anti-wrinkle injection Botox.
The company has received a big boost from Botox over the past several years, but investors are now looking at Allergan's pipeline for future drivers of growth.
"Many key R&D programs have made steady progress and we now anticipate five regulatory approvals over the next 18 months," Chief Executive Officer Brent Saunders said.
Saunders, who stitched together the current version of Allergan through a series of deals to roll up several pharmaceutical companies in 2014, recently survived a vote to split the CEO and chairman roles.
Allergan's pipeline suffered a setback earlier this year when its much-touted depression treatment rapastinel failed clinical trials, leading the company to book a charge of $2.5 billion in the first quarter.
The drug failed three late-stage studies in March, deepening investor concerns around the drugmaker's pipeline as several of its key drugs face increasing competition.
Total Botox sales rose 6.3 percent to $868.4 million. Sales of dry-eye drug Restasis, which is expected to face competition from cheaper generic drugs, fell 11.7 percent to $242.1 million, because of lower net pricing.
"The raise in 2019 guidance is not unexpected, in our view, given the lack of generic entrants to Restasis," Citi analyst Liav Abraham said.
Excluding items, the company earned $3.79 per share, well above the average analyst estimate of $3.55, according to Refinitiv IBES data.
Revenue fell 2 percent to $3.59 billion but beat the average Wall Street estimate of $3.54 billion.
The company said it now expects 2019 adjusted profit to be greater than $16.55 per share, compared with its prior expectation of profit greater than or equal to $16.36 per share.
Allergan now expects 2019 sales between $15.13 billion and $15.43 billion, compared with its prior forecast of $15.00 billion to $15.30 billion.
(Reporting by Manojna Maddipatla and Manas Mishra in Bengaluru Editing by Saumyadeb Chakrabarty)